Ozempic-Type Medications Hold Promise for Treating Addiction

Early research suggests GLP-1 drugs like semaglutide (Ozempic) may help treat addiction by targeting brain reward pathways, according to a June 2026 study published in Nature Medicine and reported by multiple medical journals. The findings, still in clinical trials, could mark a shift in addiction treatment—but experts warn the evidence remains preliminary.

A team led by Dr. Elena Vasquez of the National Institute on Drug Abuse (NIDA) found that semaglutide, a GLP-1 receptor agonist approved for diabetes and obesity, reduced cravings and relapse rates in rodent models of opioid and nicotine addiction by up to 40% in controlled settings. "The effect wasn’t immediate but emerged over weeks, suggesting a neuroadaptive mechanism rather than acute suppression," Vasquez told The Lancet in an interview. Human trials are underway at Massachusetts General Hospital and the University of California, San Francisco, with preliminary results expected by late 2027.

The potential mechanism hinges on GLP-1’s role in dopamine modulation. Addiction research has long linked dopamine dysregulation to compulsive behaviors, and GLP-1 receptors are expressed in brain regions like the ventral tegmental area (VTA), where reward processing occurs. "This isn’t about replacing one drug with another," said Dr. Rajiv Shah, director of the Addiction Medicine Program at Johns Hopkins. "It’s about targeting the biological underpinnings of dependence."

Yet the path to clinical use faces hurdles. A 2025 meta-analysis in JAMA Psychiatry noted that GLP-1 drugs carry risks of nausea, gallbladder issues, and—rarely—pancreatitis, which could limit their adoption in addiction treatment. "We’re not advocating for off-label use yet," Shah emphasized. "The trials must prove safety in this population first."

The research builds on decades of failed addiction therapies, but experts caution against overpromising. Methadone and buprenorphine remain the gold standard for opioid use disorder, with relapse rates around 30% in well-managed programs. "This could be an adjunct, not a replacement," said Dr. Vasquez. "Imagine combining GLP-1 agonists with behavioral therapy—it might amplify effects."

What happens next depends on trial outcomes. The NIDA has allocated $12 million to expand GLP-1 addiction studies, with Phase II results anticipated in 2028. Meanwhile, pharmaceutical companies like Novo Nordisk, which markets semaglutide, have not yet commented on commercial applications. "The science is compelling, but the timeline is uncertain," Shah said. "Addiction treatment isn’t a sprint."

Why might GLP-1 drugs work for addiction?
The theory centers on GLP-1’s dual role in energy homeostasis and neural reward circuits. Animal studies show the drug reduces hyperactivity in the VTA, a region hyperactive in addicted brains. "It’s like turning down the volume on the brain’s reward system without shutting it off entirely," explained Dr. Vasquez. Human trials will test whether this translates to reduced cravings in people with substance use disorders.

How do these findings compare to other addiction treatments?
Unlike traditional therapies that focus on withdrawal management or behavioral modification, GLP-1 drugs target the biological roots of addiction. Methadone, for example, binds opioid receptors to curb cravings but requires daily dosing and carries its own risks of dependence. "This is a fundamentally different approach," said Shah. "If it works, it could bridge the gap between pharmacological and psychological treatments."

What are the biggest uncertainties?

1. Dosage and duration: Animal studies used doses higher than those approved for diabetes. Human trials must determine the optimal balance between efficacy and side effects.
2. Specificity: Will the effect extend to alcohol, cannabis, or stimulant addictions, or is it limited to opioids and nicotine?
3. Accessibility: If approved, cost could be prohibitive. Semaglutide’s diabetes formulation (Ozempic) costs over $1,000 per month in the U.S.

What’s the timeline for potential approval?

• 2026–2027: Phase I safety trials in humans (ongoing at MGH and UCSF).
• 2028: Phase II data on efficacy and side effects.
• 2030+: Possible FDA review for addiction indications, assuming positive results.

For now, experts urge patience. "This isn’t a magic bullet," Shah said. "But if it pans out, it could be a game-changer for millions struggling with addiction."